Orthofix Medical Inc. (NASDAQ:OFIX) Director Alan Lee Bazaar Buys 2,250 Shares

Orthofix Medical Inc. (NASDAQ:OFIX - Get Free Report) Director Alan Lee Bazaar purchased 2,250 shares of the company's stock in a transaction that occurred on Wednesday, June 4th. The stock was acquired at an average cost of $10.92 per share, with a total value of $24,570.00. Following the purchase, the director now directly owns 30,983 shares of the company's stock, valued at $338,334.36. This trade represents a 7.83% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Orthofix Medical Stock Performance

Shares of OFIX stock traded up $0.12 during mid-day trading on Friday, reaching $10.83. 247,243 shares of the company's stock traded hands, compared to its average volume of 272,992. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.11 and a current ratio of 2.39. The firm has a market capitalization of $424.33 million, a PE ratio of -3.45 and a beta of 0.80. Orthofix Medical Inc. has a 12 month low of $10.50 and a 12 month high of $20.73. The firm has a 50 day moving average price of $12.92 and a two-hundred day moving average price of $16.13.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Rhumbline Advisers raised its position in shares of Orthofix Medical by 1.2% during the 4th quarter. Rhumbline Advisers now owns 54,989 shares of the medical device company's stock valued at $960,000 after buying an additional 661 shares in the last quarter. Invesco Ltd. increased its position in shares of Orthofix Medical by 1.0% during the 4th quarter. Invesco Ltd. now owns 74,977 shares of the medical device company's stock valued at $1,309,000 after purchasing an additional 767 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Orthofix Medical by 4.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,348 shares of the medical device company's stock worth $338,000 after acquiring an additional 836 shares during the last quarter. Gamco Investors INC. ET AL boosted its stake in shares of Orthofix Medical by 1.0% during the 1st quarter. Gamco Investors INC. ET AL now owns 157,100 shares of the medical device company's stock worth $2,562,000 after purchasing an additional 1,500 shares during the period. Finally, Swiss National Bank lifted its stake in Orthofix Medical by 2.6% in the fourth quarter. Swiss National Bank now owns 67,600 shares of the medical device company's stock worth $1,180,000 after purchasing an additional 1,700 shares during the last quarter. Institutional investors own 89.76% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Canaccord Genuity Group reiterated a "buy" rating and set a $24.00 price target on shares of Orthofix Medical in a research report on Wednesday, February 26th. Wall Street Zen downgraded Orthofix Medical from a "buy" rating to a "hold" rating in a report on Wednesday, May 7th. JMP Securities restated a "market perform" rating on shares of Orthofix Medical in a report on Friday. Finally, Roth Mkm reissued a "buy" rating and set a $22.00 price target on shares of Orthofix Medical in a research report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $23.33.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.